[Treatment of 100 acute myeloid leukemias (author's transl)]. 1979

D Fière, and C Martin, and H Vu Van, and B Coiffier, and P Felman, and P A Bryon, and J Favre-Gilly, and L Revol

Between november 1974 and august 1976, 100 acute myeloïd leukemias were treated by the same protocol L. 275. Induction treatment was daunorubicine, vincristine, cytosine arabinoside, in one intensive course for patients under 65 and cyclophosphamide (CPM), VCR and CAR in a less intensive and repetitive courses for patients over 65. In remission, there were three phases: consolidation, prevention of central nervous system leukemia, maintenance. All patients in remission received an androgenotherapy and two groups were randomised: chemotherapy and chemotherapy plus BCG. 68 patients were in complet remission (CR) 61 out of 80 patients under 65 and 7 out of 20 over 65. Median duration of first remission was 12 months. Median duration of survival was 13 months for all patients, 15 months for patients under 65, 3 months for patients over 65, and 22 months for 68 patients in CR. Survival of patients receiving BCG was slightly better than patients without BCG.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D Fière, and C Martin, and H Vu Van, and B Coiffier, and P Felman, and P A Bryon, and J Favre-Gilly, and L Revol
January 1973, Nouvelle revue francaise d'hematologie,
D Fière, and C Martin, and H Vu Van, and B Coiffier, and P Felman, and P A Bryon, and J Favre-Gilly, and L Revol
January 1973, Revista brasileira de pesquisas medicas e biologicas,
D Fière, and C Martin, and H Vu Van, and B Coiffier, and P Felman, and P A Bryon, and J Favre-Gilly, and L Revol
February 1978, La Nouvelle presse medicale,
D Fière, and C Martin, and H Vu Van, and B Coiffier, and P Felman, and P A Bryon, and J Favre-Gilly, and L Revol
March 2008, Soins; la revue de reference infirmiere,
D Fière, and C Martin, and H Vu Van, and B Coiffier, and P Felman, and P A Bryon, and J Favre-Gilly, and L Revol
May 1980, Revue medicale de Bruxelles,
D Fière, and C Martin, and H Vu Van, and B Coiffier, and P Felman, and P A Bryon, and J Favre-Gilly, and L Revol
June 1979, Quaderni Sclavo di diagnostica clinica e di laboratorio,
D Fière, and C Martin, and H Vu Van, and B Coiffier, and P Felman, and P A Bryon, and J Favre-Gilly, and L Revol
May 1982, Blut,
D Fière, and C Martin, and H Vu Van, and B Coiffier, and P Felman, and P A Bryon, and J Favre-Gilly, and L Revol
January 1980, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
D Fière, and C Martin, and H Vu Van, and B Coiffier, and P Felman, and P A Bryon, and J Favre-Gilly, and L Revol
January 1974, Nouvelle revue francaise d'hematologie,
D Fière, and C Martin, and H Vu Van, and B Coiffier, and P Felman, and P A Bryon, and J Favre-Gilly, and L Revol
February 1978, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!